

1 **Cost-effective serological test to determine exposure to SARS-CoV-2:**
2 **ELISA based on the receptor-binding domain of the spike protein (Spike-**
3 **RBD_{N318-V510}) expressed in *Escherichia coli***

4

5 Alan Roberto Márquez-Ipiña^{1,#}, Everardo González-González^{1,2,#}, Iram Pablo Rodríguez-
6 Sánchez^{3,4}, Itzel Montserrat Lara-Mayorga^{1,5}, Luis Alberto Mejía-Manzano¹, José González-
7 Valdez¹, Rocio Ortiz-Lopez⁶, Augusto Rojas-Martinez⁶, Grissel Trujillo-de Santiago^{1,5},
8 Mario Moisés Alvarez^{1,2*}

9

10 ¹ Centro de Biotecnología-FEMSA, Tecnológico de Monterrey, CP 64849, Monterrey,
11 Nuevo León, México

12 ² Departamento de Bioingeniería, Tecnológico de Monterrey, CP 64849, Monterrey, Nuevo
13 León, México

14 ³ Universidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Laboratorio de
15 Fisiología Molecular y Estructural. 66455, San Nicolás de los Garza, NL, México.

16 ⁴ Alfa Medical Center, Guadalupe, CP 67100, NL, México.

17 ⁵ Departamento de Ingeniería Mecatrónica y Eléctrica, Tecnológico de Monterrey, CP
18 64849, Monterrey, Nuevo León, México

19 ⁶ Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud y Hospital San
20 José TecSalud, CP 64718, Monterrey, Nuevo Leon, Mexico

21

22 *Corresponding authors. E-mails: mario.alvarez@tec.mx

23 # These authors contributed equally.

24

25 Abstract

26 Massive worldwide serological testing for SARS-CoV-2 is needed to determine the extent
27 of virus exposure in a particular region, the ratio of symptomatic to asymptomatic infected
28 persons, and the duration and extent of immunity after infection. To achieve this aim, the
29 development and production of reliable and cost-effective SARS-CoV-2 antigens is critical.

30 Here, we report the bacterial production of the peptide S-RBD_{N318-V510}, which contains the
31 receptor binding domain of the SARS-CoV-2 spike protein. We purified this peptide using
32 a straightforward approach involving bacterial lysis, his-tag mediated affinity
33 chromatography, and imidazole-assisted refolding. The antigen performances of
34 S-RBD_{N318-V510} and a commercial full-length spike protein were compared in two distinct
35 ELISAs. In direct ELISAs, where the antigen was directly bound to the ELISA surface,
36 both antigens discriminated sera from non-exposed and exposed individuals. However, the
37 discriminating resolution was better in ELISAs that used the full-spike antigen than the S-
38 RBD_{N318-V510}. Attachment of the antigens to the ELISA surface using a layer of anti-
39 histidine antibodies gave equivalent resolution for both S-RBD_{N318-V510} and the full length
40 spike protein.

41 Our results demonstrate that ELISA-functional SARS-CoV-2 antigens can be produced in
42 bacterial cultures. S-RBD_{N318-V510} is amenable to massive production and may represent a
43 cost-effective alternative to the use of structurally more complex antigens in serological
44 COVID-19 testing.

45

46 To be submitted to *Analytical Methods*

47

48 **Key words:** SARS-CoV-2, COVID-19, ELISA, serological testing, spike, receptor binding domain,
49 *Escherichia coli*, antigen

50

51 Introduction

52 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of
53 the coronavirus disease 19 (COVID-19) has infected more than 28 million people¹, at the

54 time of this writing. Never before in contemporary history has humankind faced an
55 infectious disease at this scale.

56 Massive worldwide serological testing is needed to determine the relevant epidemiological
57 indicators related to COVID-19 infection, including the extent of the exposure, the ratio of
58 symptomatic to asymptomatic infected persons, and the duration and extent of immunity
59 after infection²⁻⁵. Moreover, as vaccines are developed, tested in animal models and
60 humans, and applied to open populations, we will depend on assays for reliable and
61 quantitative characterization of the immune responses associated with the administration of
62 a vaccine to determine the level of immunization conferred^{2,6}.

63 Fortunately, the time kinetics of the various antibodies (IgAs, IgMs, and IgGs) produced
64 against SARS-CoV-2 in COVID-19 patients has been well described in recent reports⁷. For
65 instance, we know that the determination of IgGs 15 days after viral exposure is a good
66 indicator of a previous infection. Several semi-automated serological assays are
67 commercially available to determine the likelihood of infection⁸⁻¹⁰. Most established
68 commercial platforms perform well, in terms of accurate prediction of infection in
69 convalescent patients, when the analysis is performed 15 days (or more) after a possible
70 contact¹⁰. However, despite this reliability, automated serological platforms are expensive
71 when compared to other techniques, such as regular enzyme-linked immunoassays
72 (ELISAs).

73 ELISAs continue to be the most reliable and widely used method for characterization of the
74 amount of antibodies developed against a specific antibody^{10,11}. Laboratories around the
75 world, and particularly in developing countries, depend on traditional ELISAS to conduct
76 widespread serological testing. Therefore, reliable and cost-effective antigens for ELISA

77 testing are greatly needed.

78 In the context of COVID-19 research, a limited number of reports have been published on
79 the development and characterization of SARS-CoV-2 antigens for ELISAs¹²⁻¹⁵. The Spike
80 protein (S)^{16,17} and the nucleocapsid protein (N)¹⁸ of SARS-CoV-2 have been used for
81 COVID-19 serological diagnostic¹³. However, only a few detailed reports have been made
82 available on the characterization of ELISAs for the identification of anti-SARS-CoV-2
83 antibodies.^{5,12,13,19} Most of these reports describe transient mammalian cell expression^{12,14,20}
84 of the entire spike protein of SARS-CoV-2, or a fraction of the spike protein containing the
85 RBD receptor binding domain²⁰.

86 Here, we report the production of an antigen inspired by the structure of the receptor
87 binding domain (RBD)²⁰ of the spike protein of SARS-CoV-2. This antigen is produced by
88 bacterial culture of *Escherichia coli*, which enables massive production at low cost²¹. In
89 addition, we characterize and contrast the performance of two ELISA versions, involving
90 (a) direct attachment of the antigen to the surface of plates or (b) the use of a bed of anti-
91 histidine antibodies (anti-his-mediated ELISA) to engineer the reactive surface.

92


93 **Results and discussion**

94 **Antigen design and production**

95 We engineered an expression construct for the recombinant production of the RBD of the S
96 protein of SARS-CoV-2. Specifically, we selected the region of the S-RBD between the
97 residues N318 and V510 of the consensus sequence of the S protein of SARS-CoV-2.

98 In a recent report, a similar fraction of the SARS-CoV-2 spike protein (from residues 331 to

99 510) containing the RBD has been transiently expressed in HEK293 cells.²⁰ That peptide
100 successfully recognized the ACE receptor, the native target of the RBD of the spike
101 protein²⁰. Our construct also contained a region for the expression of M FH8, an
102 enterokinase restriction site, as well as a histidine tag (his-tag). The M FH8 provides the
103 means to facilitate purification and increase solubility of the product²².



104

105 **Figure 1. Expression of S-RBD_{N318-V510} in *Escherichia coli*.** (A) Schematic representation of the
106 sequence used to produce the MFH8-RBD_{Spike}-HisTag protein (S-RBD_{N318-V510}). This expression
107 cassette was inserted into the (B) pFH-RBD SARS-CoV-2 plasmid for expression in *E. coli*. (C)
108 Molecular 3D structure of the S-RBD_{N318-V510} protein, as predicted by molecular structure
109 simulations.

110


111 The his-tag provides an additional handle for separation using his-tag affinity columns
112 (loaded with divalent ions such as Ni⁺²). In addition, antigenic proteins containing histidine
113 tags can be fixed to surfaces through anti-histidine antibodies to enable ELISA serological
114 assays using his-tagged antigens^{21,23}. Figure 1a schematically shows the sequence that we

115 used to encode and produce the MFH8-RBD_{Spike}-HisTag protein (S-RBD_{N318-V510} for short).
116 This expression cassette was inserted in a plasmid for expression in *E. coli*. Figure 1c
117 shows the molecular 3D structure of this product, as predicted by molecular structure
118 simulations.

119 We cloned the construct for the production of S-RBD_{N318-V510} in *E. coli* BL21 strain C41.
120 High-producer clones were further cultured using Luria-Bertani (LB) medium in
121 Erlenmeyer flasks and recombinant expression was induced using isopropyl β -d-1-
122 thiogalactopyranoside (IPTG). Reproducible productions of up to 2 g (dry weight) of
123 biomass L⁻¹ was obtained in 2 L Erlenmeyer flasks incubated in orbital shakers at 30 °C for
124 12 h (Figure 2A). At this point, this production process has not yet been scaled up to an
125 instrumented bioreactor. However, based on our previous work with other antigens
126 expressed in bacterial systems, we anticipate that this scale-up will further increase biomass
127 production to 10–20 g L⁻¹.²⁴

128 **Recovery and purification**

129 The methods described here lead to the production of S-RBD_{N318-V510} in inclusion bodies
130 (IBs); we found negligible amounts of the protein in the supernatant of *E. coli* cultures. We
131 implemented a conventional separation purification protocol that included lysis in a high-
132 throughput homogenizer, filtration, re-suspension, and purification using his-tag columns
133 (Figure 2). Lysis experiments were conducted in a high pressure homogenizer operated at
134 5000 Psi (first cycle) and 20,000 Psi in two subsequent cycles (Figure 2B).



135

136 **Figure 2. Production process for obtaining S-RBD_{N318-V510} from Escherichia coli cultures.**

137 Schematic representation of the general production process for S-RBD_{N318-V510}. (A) Culture of a
138 recombinant BL21 C41 strain of *E. coli* engineered to produce S-RBD_{N318-V510}, (B) cell lysis in a
139 continuous homogenizer, (C) and purification through several stages of affinity chromatography, in-
140 column refolding, and elution.

141

142 After lysis, different refolding and purification strategies were tested, including the use of
143 different columns and combinations of resuspension buffers and conditions. The best
144 results were obtained by suspending the cell pellet in IB washing buffer at a ratio of 25 mL
145 per g of IB pellet (wet weight), centrifuging to recover the pellet, washing with PBS, and
146 re-suspending in IB solubilization imidazole-based buffer (Figure 2C).

147 The S-RBD_{N318-V510} protein was then purified by immobilization metal-affinity
148 chromatography in a preparative chromatography system (Figure 2D). After testing
149 different purification protocols, we opted for a two-phase purification protocol (as

150 described in Materials and Methods).


151 Western blots conducted using marked anti-histidine antibodies indicated that the
152 recombinant product was produced and could be purified with sufficient yield and purity by
153 the methods described here. The molecular weight of the S-RBD_{N318-V510} protein
154 (approximately 31 kDa) was consistent with the expected value. The degree of purity of the
155 RBD was estimated at approximately 92% based on the SDS-PAGE protein profiles and
156 using the Image J open source software for scanning densitometry analysis. We have
157 consistently obtained overall yields of approximately 1.5 mg of pure S-RBD_{N318-V510} per
158 liter of culture medium among different batches.

159

160 **Determination of binding affinity**

161 We evaluated the binding affinity of the S-RBD_{N318-V510} protein in two sets of ELISA
162 experiments using commercial anti-RBD antibodies.

163 In the first set of experiments (direct ELISAS; Figure 3A), we directly deposited 1 µg of
164 purified S-RBD_{N318-V510} per well in 96-well plates. We then added a commercial
165 anti-S(RBD) antibody to each well, and the relative amount of antibody bound to S-
166 RBD_{N318-V510} protein was determined by absorbance after the addition of an anti-heavy
167 chain antibody marked with horseradish peroxidase (HRP). The S-RBD_{N318-V510} protein
168 exhibited a binding affinity of approximately $75.51 \pm 5\%$ of that of the commercial control
169 (Figure 3B).



170

171 **Figure 3. Contrast of two versions of ELISAs for identification of anti-Spike SARS-CoV-2**
172 **antibodies.** Comparison of a commercial full-length spike protein from SARS-CoV-2 (red circles)
173 and the S-RBD_{N318-V510} protein (blue circles) produced in *Escherichia coli* as antigens in ELISA
174 experiments performed to identify anti-spike SARS-CoV-2 antibodies. The antigen was (A) directly
175 bound to the surface of 96-well plates, or (B) bound through a layer of anti-histidine antibodies
176 (pink Ys). In both cases, the specific attachment of anti-spike SARS-CoV-2 antibodies (blue Ys)
177 was revealed by binding of anti-human heavy chain antibodies functionalized with horse-radish
178 peroxidase (yellow Ys). Comparison of absorbance readings for (C) direct ELISAs or (D) anti-
179 histidine mediated ELISAs. A commercial full-length spike (red bars) or the S-RBD_{N318-V510} protein
180 (blue bars) were used as antigens. Commercially available anti-spike SARS-CoV-2 antibodies were
181 used as reactants.

182

183 In the second set of experiments, we conducted sandwich-type ELISAs (Figure 3C). For
184 that purpose, the S-RBD_{N318-V510} protein was bound to the bottom surface of the 96-well
185 plates through an anti-histidine antibody.²¹ In concept, this strategy may promote a more
186 uniform orientation of the S-RBD_{N318-V510} protein and thereby improve the selectivity of the
187 assay. Indeed, the binding ability of S-RBD_{N318-V510} protein was $26.63 \pm 5\%$ higher than


188 that shown by the commercially available spike protein used here as a positive control
189 (Figure 3D).

190 **Determination of binding affinity using human sera**

191 We ran an additional series of ELISA experiments using actual human sera and contrasted
192 the results with those of the two ELISA versions previously discussed.

193 In a first round of experiments, we directly bound commercial spike protein or S-RBD_{N318-}
194 v₅₁₀ protein to 96-well ELISA plates. First, we used 5 serum samples from non-exposed
195 individuals collected from June to December 2009 during the first wave of pandemic
196 Influenza A/H1N1/2009 in México. The average absorbance value exhibited by samples of
197 these non-exposed individuals was 0.272 (99% CI 0.243 to 0.301) in ELISAs conducted
198 using the S-RBD_{N318-V510} protein. Similarly, the average absorbance value for non-exposed
199 individuals when the whole spike protein was used was 0.198 (99% CI 0.168 to 0.224).
200 Sera from non-exposed individuals exhibited low absorbance values and enabled the
201 definition of an average reliable absorbance value for non-exposed individuals (first two
202 bars in Figure 4A,B). Figure 4A and 4B show the absorbance readings from direct ELISA
203 experiments conducted on a set of selected serum samples. In this set, we included sera
204 from non-exposed COVID-19 individuals (the samples collected in 2009). We also selected
205 samples from probably exposed individuals that exhibited absorbance values statistically
206 similar to negative samples, as well as sera from convalescent patients diagnosed as
207 COVID-19 (+) by RT-qPCR. The performance of the S-RBD_{N318-V510} protein (blue bars)
208 and a commercial spike protein (magenta bars) was compared. Some of the samples
209 exhibited values that exceeded the thresholds of the 99.5% confidence values for
210 serologically negative samples. Consistently, these samples corresponded to sera from

211 convalescent COVID-19 patients.



212

213 **Figure 4. Binding of antibodies from human sera to S-RBD_{N318-V510} using direct and**

214 **anti-histidine-mediated ELISAs.** (A) Binding of antibodies from human sera, measured as

215 absorbance readings, in direct ELISA experiments that used a commercial full-length spike (red

216 bars) or the S-RBD_{N318-V510} protein (blue bars) as antigens. Serum samples were obtained from non-

217 exposed volunteers (FLU X; collected during pandemic Influenza A/H1N1/2009) and from

218 volunteers possibly exposed to SARS-CoV-2 (COVID X; collected during pandemic COVID-19).

219 NEG bars indicate the average absorbance reading exhibited by serum samples from non-exposed

220 volunteers. (B) Absorbance readings in direct ELISA experiments that used the S-RBD_{N318-V510}

221 protein as the antigen. (C) Binding of antibodies from human sera, measured as absorbance

222 readings, in anti-histidine mediated ELISA experiments that used a commercial full-length spike

223 (red bars) or the S-RBD_{N318-V510} protein (blue bars) as antigens. Serum samples were obtained from

224 non-exposed volunteers (FLU X; collected during pandemic Influenza A/H1N1/2009) and from

225 volunteers possibly exposed to SARS-CoV-2 (COVID X; collected during pandemic COVID-19).

226 NEG bars indicate the average absorbance reading exhibited by serum samples from non-exposed

227 volunteers. (D) Graphic analysis of the correlation between titers obtained in anti-histidine-

228 mediated ELISAs that used the commercial full-length spike (red bars) or the S-RBD_{N318-V510} protein

229 (blue bars) as antigens. All experiments were conducted using 1:100 serum dilutions.

230

231

232 Both the full-length commercial spike antigen and the S-RBD_{N318-V510} protein antigen were


233 able to discriminate between samples from non-exposed individuals and COVID-19 (+)
234 patients. However, consistent with recent reports²⁵, the absorbance values were much
235 higher when the full-length commercial spike protein was used as the ELISA antigen than
236 when the S-RBD_{N318-V510} protein was used. Therefore, in this ELISA format, the difference
237 in absorbance value between positive and negative samples was greater when the spike
238 protein was used than when the S-RBD_{N318-V510} protein is used.

239 We repeated these ELISA experiments using a second strategy consisting of binding the
240 antigens through a layer of anti-histidine antibodies. Figure 4C shows the results of a
241 parallel ELISA experiment using a layer of anti-histidine antibodies to bind the antigens to
242 the plate surfaces.

243 The average absorbance value for non-exposed individuals was 0.257 (99% CI 0.237 to
244 0.277) and 0.255 (99% CI 0.226 to 0.284) for the full-length spike and the S-RBD_{N318-V510}
245 protein, respectively. In general, the absolute values of the absorbance readings were lower
246 in the anti-histidine-mediated ELISAs than in the direct ELISAs. The absorbance readings
247 produced using the full spike and S-RBD_{N318-V510} were remarkably similar (Figure 4C and
248 D). This suggests that the anti-histidine antibodies allow similar arrangement and alignment
249 of both antigens to present reactive surfaces of comparable antibody binding capacity.

250 We further studied the usefulness of these two ELISA versions (direct or mediated by anti-
251 histidine antibodies) by testing 50 samples from convalescent patients diagnosed as
252 COVID-19 (+) by RT-qPCR. Most of these patients had shown COVID-19-related
253 symptoms at least 7 days before blood collection. Figure 5A shows the normalized
254 absorbance readings for this set of serum samples, with no particular order, as determined
255 by ELISA testing conducted by direct sensitization of the reactive surface with

256 S-RBD_{N318-V510}. Figure 5B shows results from ELISAs that used an anti-histidine-mediated
257 binding to sensitize the reaction with S-RBD_{N318-V510}. The normalization of the absorbance
258 values consisted of dividing the absolute absorbance by the average value of absorbance
259 readings of sera from three non-exposed individuals.



260

261 **Figure 5. Binding of S-RBD_{N318-V510} serum samples donated by convalescent patients**
262 **confirmed as COVID-19 (+) by RT-qPCR.** Normalized absorbance readings related to
263 the binding affinity of the S-RBD_{N318-V510} protein to human sera antibodies from COVID-19
264 convalescent patients for (A) direct, and (B) anti-histidine mediated ELISAs. All
265 absorbance readings were normalized by the average absorbance reading exhibited by
266 samples from non-exposed individuals. Normalized readings higher than the threshold
267 value of 1.11 (for direct ELISAs) or 1.12 (for anti-histidine-mediated ELISAs) are
268 indicated in blue. Absorbance readings from blanks (phosphate buffered saline only) are
269 indicated in yellow as a reference. Experiments were conducted using 1:100 serum
270 dilutions.

271

272 We also established threshold values for normalized absorbance to discriminate between
273 the negative and positive results for threshold values of normalized absorbance of 1.11 and
274 1.12 for direct and anti-histidine mediated ELISAs using S-RBD_{N318-V510}, respectively.
275 These values were slightly above the upper threshold of the 99% CI for readings of non-
276 exposed individuals.

277 The results of both ELISA formats were highly consistent (Figure %A-C). As shown
278 earlier, anti-his-mediated ELISAs yielded similar results, regardless of the use of the full-
279 length spike protein or S-RBD_{N318-V510}. Therefore, we assumed that the anti-his-mediated
280 results correlated well with ELISAs conducted with the full spike protein and can be taken
281 as a reference for determining the sensibility and specificity of direct ELISAs performed
282 using S-RBD_{N318-V510}. When this is done, the selectivity and specificity of the direct
283 S-RBD_{N318-V510} format are 97.2% and 52.0 %, respectively, when a threshold value of
284 normalized absorbance of 1.10 is used. If a threshold value of normalized absorbance of
285 1.25 is used instead, the values of selectivity and specificity are 97.2% and 68.0%,
286 respectively. The overall accuracy of the direct S-RBD_{N318-V510} ELISA test (i.e., the overall
287 consistency of the results with respect to the anti-his S-RBD_{N318-V510} ELISA) was 81.8%
288 and 85.45% when the thresholds were set at 1.10 and 1.25, respectively.

289 Overall, the results suggest that the anti-his S-RBD_{N318-V510} ELISA is more consistent with
290 full-length spike ELISAs. However, direct S-RBD_{N318-V510} ELISA can be used in
291 serological testing (further reducing the cost) with only a minimum sacrifice of selectivity,
292 but with an increased probability of false positives.

293

294 **Conclusions**

295 Arguably, antigens are one of the most important reagents that clinicians will require while
296 facing COVID-19 pandemics in the months to come. Here, we report methods for the
297 production of a portion of the S1 fraction of the SARS-CoV-2 spike protein that contains
298 the receptor-binding domain for the Angiotensin II human receptor.

299 We chose *Escherichia coli* as an expression host, and we describe a straightforward
300 process, amenable to widespread implementation, for the production and purification of the
301 S-RBD_{N318-V510} protein. Our aim was to enable the widespread use of this simple process to
302 produce a cost-effective SARS-CoV-2 antigen. In ELISA experiments using commercial
303 anti-spike antibodies or actual sera from patients, this protein performs similarly to
304 commercially available antigens based on the expression of larger segments of the spike
305 protein.

306 The fact that our antigen is expressed in bacterial systems greatly facilitates its production
307 and paves the way to scaling up. We show that antigen production of 1.5 mg per L is
308 feasible, even when using non-agitated Erlenmeyer flasks and non-instrumented
309 bioreactors. This production level is already attractive, since production can be completed
310 in 24 h. Complete COVID-19 ELISA kits are commercially available but their cost
311 (approximately 8 USD per reaction per well) still limits massive implementation,
312 particularly in developing economies. The current value of commercially available S1-
313 derived SARS-CoV-2 antigens is approximately 7 USD μg^{-1} , which is also prohibitive for
314 most laboratories for large-scale screening of COVID-19 seropositive subjects. We believe
315 that a lab-scale manufacturing operation based on the process described here may allow the
316 production of gram amounts of antigen per month of satisfactory quality to enable mass-
317 scale screening projects in open populations.

318 **Materials and methods**

319 **Design of S-RBD_{N318-V510} and prediction of its 3D structure**

320 We used the Geneious 11.1.5 software (Biomatters, Ltd., New Zealand) to design the vector
321 pFH8-RBD SARS-COV2 that contained the RBD (region of 193 aa from N318-V510) of
322 the SARS-CoV-2 spike protein. Histidine and FH8 tags were added for use in the
323 purification process. The 3D structure of the RBD protein with tags was predicted using the
324 software I-TASSER server (University of Michigan, USA).

325 **Cloning and transformation**

326 The full spike coding sequence was synthesized by Genscript (New Jersey, USA) and was
327 used to obtain the sequences comprising the RBD. This sequence was cloned in an
328 expression vector (ATUM, CA, USA) regulated by a T7 promoter (IPTG-inducible) using a
329 SapI restriction site and T4 DNA ligase (New England Biolabs, UK). The expression vector
330 was transformed into chemical-competent *E. coli* C41 cells (Lucigen Corporation, WI,
331 USA) to obtain a producer clone.

332 **RBD production in Erlenmeyer flasks**

333 The highest producer clone was cultured in Luria-Bertani broth containing 50 µg/mL
334 ampicillin (LB-Amp) in 2L Erlenmeyer flasks. For the initial growth, 200 mL of LB-Amp
335 broth was maintained overnight at 37°C with 250 rpm agitation in an orbital shaker (VWR
336 International, USA). After 12 h of culture, cells were harvested using a Z36 HK centrifuge
337 (Hermle Labortechnik, Germany) at 5000 × g for 10 min. The cell pellet was then

338 resuspended in fresh LB-Amp broth containing 1 mM isopropyl β -d-1-
339 thiogalactopyranoside (IPTG) to induce RBD production. The induction was conducted at
340 30°C with agitation at 250 rpm for 8–12 h. After induction, cells were recovered by
341 centrifugation at 5000 \times g for 10 min at 4°C. Cell pellets were kept at -20°C until further
342 processing.

343 **S-RBD_{N318-V510} recovery and purification**

344 Pellets from IPTG-induced cells were re-suspended in PBS buffer (pH=7.4) containing 100
345 mM NaCl in a proportion of 7.5 mL per gram of cells (wet weight). The cells were then
346 disrupted in an EmulsiFlex-C3 high-pressure homogenizer (Avestin, Canada). The process
347 comprised 3 cycles, with the first cycle set to reach 5000 psi and the following two cycles
348 performed at 20000 psi. Cell lysates were centrifuged at 15,000 \times g for 30 min at 4°C in a
349 Z36 HK centrifuge. The pellet containing the IB was re-suspended in IB wash buffer (PBS,
350 pH=7.4, 1mM EDTA, 500 mM NaCl, 2 M urea, and 2% Triton X-100) at a ratio of 25 mL
351 per g of IB pellet (wet weight), centrifuging to recover the pellet, washing with PBS, and
352 re-suspending in IB solubilization buffer (PBS, pH=8.0, 500 mM NaCl, 8 M Urea, 2.5 mM
353 2-mercaptoethanol, and 10 mM imidazole) (Figure 2C).

354 The S-RBD_{N318-V510} protein was then purified by immobilization metal-affinity
355 chromatography in a preparative chromatography system (Figure 2D). After testing
356 different purification protocols, we opted for a two-phase purification protocol. Phase A
357 consisted of 20 mM PBS, 300 mM NaCl, and 20 mM imidazole, pH=7.4, and phase B was
358 20 mM PBS pH = 7.4, 300 mM NaCl, and 300 mM imidazole at pH=7.4. The purification
359 protocol was set with an initial equilibrium of 10 column volumes (CV) of phase A and a

360 flow rate of 1 mL/min. A 5 mL sample of protein was injected at a flow rate of 0.5 mL/min.
361 After sample injection, a washing step of 8 CV was set at a flow rate of 1 mL/min, followed
362 by elution with 3 CV of a linear gradient from 0 to 80% of phase B, then 10 CV of 20/80%
363 phase A/B, and finally 5 CV of 100% phase B, all at a flow rate of 1 mL/min. Finally, to
364 prepare for further purifications, the column was re-equilibrated with 5 CV of phase A at 1
365 mL/min. The fraction containing the protein of interest was recovered based on the
366 chromatogram and stored at 4°C.

367 This suspension was vigorously washed for 30 min at room temperature and then
368 centrifuged at $15,000 \times g$ for 30 min. The resultant pellet was gently washed with PBS to
369 eliminate the excess Triton X-100 and then resuspended in IB solubilization buffer. This
370 suspension was then vigorously stirred overnight at room temperature and finally
371 centrifuged at $15,000 \times g$ for 30 min at 4°C. The supernatant containing the solubilized IBs
372 was recovered, filtered through a 0.2 μm syringe filter, and stored at 4°C.

373 The S-RBD_{N318-V510} protein was purified by immobilized metal-affinity chromatography
374 (IMAC), using a HiTrap™ column (GE Healthcare, UK) packed with 1 mL Ni²⁺ charged
375 agarose Ni-NTA Superflow (Quiagen, Germany) in an Äkta Pure system (GE Healthcare,
376 UK) chromatography system,. The degree of purity of S-RBD_{N318-V510} was estimated from
377 SDS-PAGE protein profiles using Image J, an open source software for scanning
378 densitometry analysis.

379 A dual phase separation strategy was implemented. Phase A consisted of 20 mM PBS, 300
380 mM NaCl, and 20 mM imidazole, pH=7.4, and phase B was 20 mM PBS pH = 7.4, 300
381 mM NaCl, and 300 mM imidazole at pH=7.4. The purification protocol was set with an
382 initial equilibrium of 10 column volumes (CV) of phase A and a flow rate of 1 mL/min. A

383 5 mL sample of protein was injected at a flow rate of 0.5 mL/min. After sample injection, a
384 washing step of 8 CV was set at a flow rate of 1 mL/min, followed by elution with 3 CV of
385 a linear gradient from 0 to 80% of phase B, then 10 CV of 20/80% phase A/B, and finally 5
386 CV of 100% phase B, all at a flow rate of 1 mL/min. Finally, to prepare for further
387 purifications, the column was re-equilibrated with 5 CV of phase A at 1 mL/min. The
388 fraction containing the protein of interest was recovered based on the chromatogram and
389 stored at 4°C.

390

391 **ELISA assays**

392 We developed and characterized two ELISA strategies for the evaluation of presence of
393 specific anti-SARS-CoV-2 antibodies (Figure 3), as described in the Results and
394 Discussion. Standard commercial 96-wells micro-assay plates (CorningH, Maxisorp™;
395 USA) were used.

396 In the first format, 100 µL of 1 µg/mL RBD in PBS was dispensed into each well and
397 incubated for 8 h at 4°C, followed by addition of 100 µL 5% skim milk in PBS and further
398 incubation for 1 h at room temperature, and then three washes with PBS containing 0.05%
399 Tween-20™. Rabbit anti-COVID-19 pAb (100 µL; 1:2000 dilution; Sino Biological Inc.,
400 PA, USA) was then added incubated for 1 h at room temperature, followed by three washes
401 with PBS containing 0.05% Tween-20™. The presence of rabbit antibodies was revealed
402 by adding donkey anti-rabbit-HRP (100 µL, 1:5000 dilution; Pierce, Rockford IL, USA),
403 followed by three washes with PBS containing 0.05% Tween-20™. The HRP was then
404 detected by adding 100 µL 1-Step™ Ultra TMB-ELISA (Pierce, Rockford IL, USA) until a

405 blue color was observed. The reaction was stopped by adding 100 μ L 1M H₂SO₄ and the
406 absorbance was measured at 450 nm in a Biotek microplate reader (VT US).

407 The second ELISA format consisted of first sensitizing the plate wells with mouse anti-
408 histidine pAb (100 μ L, 1:1000 dilution; Bio-Rad Laboratories, Inc., CA, USA) and
409 incubating for 8h at 4°C, then blocking with skim milk for 1 h at room temperature,
410 followed by 3 washes with PBS containing 0.05% Tween-20TM. The plates were then
411 incubated with RBD for 1 h at room temperature. All subsequent steps were as described
412 for the first ELISA format.

413 **ELISA testing of serum samples**

414 We performed ELISA experiments using samples of sera from non-exposed individuals and
415 convalescent positive volunteers. Five samples of sera from COVID-19 non-exposed
416 individuals were collected from volunteers at Hospital San José (Nuevo León, México),
417 from June 2009 to October 2009, during pandemic Influenza A/H1N1/2009. Fifty-five
418 samples of sera from convalescent patients previously confirmed as COVID-19 (+) by RT-
419 qPCR were collected at Alfa Medical S.A. de C.V. (Monterrey, N.L., México). Samples
420 were collected from patients after obtaining informed and signed written consent and in
421 complete observance of good clinical practices, the principles stated in the Helsinki
422 Declaration, and applicable lab operating procedures at Hospital Alfa. Every precaution
423 was taken to protect the privacy of sample donors and the confidentiality of their personal
424 information. The experimental protocol was approved on May 20th, 2020 by a named
425 institutional committee (Alfa Medical Center, Research Comittee; resolution AMCCI-
426 TECCOVID-001).

427 As described in the Results and Discussion section, the two different ELISA strategies were
428 contrasted. In the first format, 100 μ L of 1 μ g/mL RBD in PBS was dispensed into each
429 well of 96-well plates and incubated for 8 h at 4°C, followed by blocking with 100 μ L 5%
430 skim milk in PBS and incubation for 1 h at room temperature, and 3 washes with PBS
431 containing 0.05% Tween-20TM. Different dilutions (1:5, 1:50, 1:100 and 1:200; 100 μ L) of
432 serum from volunteers were added per well, incubated for 1 h at room temperature and then
433 washed three times with PBS containing 0.05% Tween-20TM. Best results were observed
434 when 1:100 dilutions were used. The presence of human IgG was detected by adding goat
435 anti-human IgG HRP (100 μ L; 1:10000 dilution; Pierce Biotechnology Inc., IL, USA) and
436 incubating for 1 h at room temperature, followed by three washes with PBS containing
437 0.05% Tween-20TM and detection with 1-StepTM Ultra TMB-ELISA

438 In the second format, RBD (100 μ L; 1 μ g/mL in PBS) was dispensed in each well and
439 incubated for 1 h at room temperature followed by 3 washes with PBS containing 0.05%
440 Tween-20TM. Then 100 μ L of different dilutions (1:5, 1:50, 1:100, and 1:200) of serum
441 from volunteers were added per well, incubated for 1 h at room temperature and
442 subsequently washed three times with PBS containing 0.05% Tween-20TM. The presence of
443 human IgG was again detected with goat anti-human IgG HRP and the remaining steps
444 were conducted as described for the first ELISA format.

445 **Acknowledgements:**

446 The authors acknowledge the funding provided by the Federico Baur Endowed Chair in
447 Nanotechnology (0020240I03). EGG acknowledges funding from a doctoral scholarship provided
448 by CONACyT (Consejo Nacional de Ciencia y Tecnología, México). GTdS and MMA
449 acknowledge the institutional funding received from Tecnológico de Monterrey (Grant

450 002EICIS01). MMA, GTdS, and IMLM acknowledge funding provided by CONACyT (Consejo
451 Nacional de Ciencia y Tecnología, México) through grants SNI 26048, SNI 256730, and SNI
452 1056909, respectively.

453

454 **References**

455

- 456 1 Home - Johns Hopkins Coronavirus Resource Center, <https://coronavirus.jhu.edu/>, (accessed
457 10 September 2020).
- 458 2 F. Krammer and V. Simon, *Science* (80-.), 2020, 368, 1060–1061.
- 459 3 C. Clarke, M. Prendecki, A. Dhutia, M. A. Ali, H. Sajjad, O. Shivakumar, L. Lightstone, P.
460 Kelleher, M. C. Pickering, D. Thomas, R. Charif, M. Griffith, S. P. McAdoo and M.
461 Willicombe, *J. Am. Soc. Nephrol.*, 2020, **31**, ASN.2020060827.
- 462 4 A. M. Lerner, R. W. Eisinger, D. R. Lowy, L. R. Petersen, R. Humes, M. Hepburn and M. C.
463 Cassetti, in *Immunity*, Cell Press, 2020, vol. 53, pp. 1–5.
- 464 5 V. Roy, S. Fischinger, C. Atyeo, M. Slein, C. Loos, A. Balazs, C. Luedemann, M. G.
465 Astudillo, D. Yang, D. Wesemann, R. Charles, A. J. Lafrate, J. Feldman, B. Hauser, T.
466 Caradonna, T. E. Miller, M. R. Murali, L. Baden, E. Nilles, E. Ryan, D. Lauffenburger, W.
467 G. Beltran, G. Alter and G. Alter, *J. Immunol. Methods*, 2020, **484–485**, 112832.
- 468 6 M. Lipsitch, R. Kahn and M. J. Mina, *Nat. Med.*, 2020, 26, 818–819.
- 469 7 L. Guo, L. Ren, S. Yang, M. Xiao, D. Chang, F. Yang, C. S. Dela Cruz, Y. Wang, C. Wu, Y.
470 Xiao, L. Zhang, L. Han, S. Dang, Y. Xu, Q. W. Yang, S. Y. Xu, H. D. Zhu, Y. C. Xu, Q. Jin,
471 L. Sharma, L. Wang and J. Wang, *Clin. Infect. Dis.*, 2020, **71**, 778–785.
- 472 8 R. T. Suhandynata, M. A. Hoffman, M. J. Kelner, R. W. McLawhon, S. L. Reed and R. L.
473 Fitzgerald, *J. Appl. Lab. Med.*, , DOI:10.1093/jalm/jfaa139.
- 474 9 T. Nicol, C. Lefeuvre, O. Serri, A. Pivert, F. Joubaud, V. Dubée, A. Kouatchet, A.
475 Ducancelle, F. Lunel-Fabiani and H. Le Guillou-Guillemette, *J. Clin. Virol.*, 2020, **129**,
476 104511.
- 477 10 J. Van Elslande, B. Decru, S. Jonckheere, E. Van Wijngaerden, E. Houben, P.
478 Vandecandelaere, C. Indevuyst, M. Depypere, S. Desmet, E. André, M. Van Ranst, K.
479 Lagrou and P. Vermeersch, *Clin. Microbiol. Infect.*, , DOI:10.1016/j.cmi.2020.07.038.
- 480 11 M. Lisboa Bastos, G. Tavaziva, S. K. Abidi, J. R. Campbell, L. P. Haraoui, J. C. Johnston,
481 Z. Lan, S. Law, E. MacLean, A. Trajman, D. Menzies, A. Benedetti and F. A. Khan, *BMJ*,
482 2020, **370**, 2516.
- 483 12 R. G. F. Alvim, T. M. Lima, D. A. S. Rodrigues, F. F. Marsili, V. B. T. Bozza, L. M. Higa,
484 F. L. Monteiro, I. C. Leitao, R. S. Carvalho, R. M. Galliez, T. M. P. P. Castineiras, A.
485 Nobrega, L. H. Travassos, O. C. Ferreira, A. Tanuri, A. M. Vale and L. R. Castilho,

- 486 *medRxiv*, 2020, **pre-print**, 2020.07.13.20152884.
- 487 13 P. Zhang, Q. Gao, T. Wang, Y. Ke, F. Mo, R. Jia, W. Liu, L. Liu, S. Zheng, Y. Liu, L. Li, Y.
488 Wang, L. Xu, K. Hao, R. Yang, S. Li, C. Lin and Y. Zhao, *medRxiv*, 2020,
489 2020.03.17.20036954.
- 490 14 Y. B. Johari, S. R. Jaffé, J. M. Scarrott, A. O. Johnson, T. Mozzanino, T. H. Pohle, S.
491 Maisuria, A. Bhayat-Cammack, A. J. Brown, K. Lan Tee, P. J. Jackson, T. Seng Wong, M.
492 J. Dickman, R. Sargur and D. C. James, *medRxiv*, 2020, 2020.08.07.20169441.
- 493 15 D. Esposito, J. Mehalko, M. Drew, K. Snead, V. Wall, T. Taylor, P. Frank, J. P. Denson, M.
494 Hong, G. Gulten, K. Sadtler, S. Messing and W. Gillette, *Protein Expr. Purif.*, 2020, **174**,
495 105686.
- 496 16 B. zhong Zhang, Y. fan Hu, L. lei Chen, T. Yau, Y. gang Tong, J. chu Hu, J. piao Cai, K. H.
497 Chan, Y. Dou, J. Deng, X. lei Wang, I. F. N. Hung, K. K. W. To, K. Y. Yuen and J. D.
498 Huang, *Cell Res.*, 2020, 30, 702–704.
- 499 17 Y. He, Y. Zhou, H. Wu, B. Luo, J. Chen, W. Li and S. Jiang, *J. Immunol.*, 2004, **173**, 4050–
500 4057.
- 501 18 S. Kang, M. Yang, Z. Hong, L. Zhang, Z. Huang, X. Chen, S. He, Z. Zhou, Z. Zhou, Q.
502 Chen, Y. Yan, C. Zhang, H. Shan and S. Chen, *Acta Pharm. Sin. B*, 2020, **10**, 1228–1238.
- 503 19 F. Amanat, D. Stadlbauer, S. Strohmeier, T. H. O. Nguyen, V. Chromikova, M. McMahon,
504 K. Jiang, G. A. Arunkumar, D. Jurczynszak, J. Polanco, M. Bermudez-Gonzalez, G. Kleiner,
505 T. Aydiillo, L. Miorin, D. S. Fierer, L. A. Lugo, E. M. Kojic, J. Stoever, S. T. H. Liu, C.
506 Cunningham-Rundles, P. L. Felgner, T. Moran, A. García-Sastre, D. Caplivski, A. C. Cheng,
507 K. Kedzierska, O. Vapalahti, J. M. Hepojoki, V. Simon and F. Krammer, *Nat. Med.*, 2020,
508 **26**, 1033–1036.
- 509 20 W. Tai, L. He, X. Zhang, J. Pu, D. Voronin, S. Jiang, Y. Zhou and L. Du, *Cell. Mol.*
510 *Immunol.*, 2020, **17**, 613–620.
- 511 21 M. M. Alvarez, F. López-Pacheco, J. M. Aguilar-Yañez, R. Portillo-Lara, G. I. Mendoza-
512 Ochoa, S. García-Echauri, P. Freiden, S. Schultz-Cherry, M. I. Zertuche-Guerra, D. Bulnes-
513 Abundis, J. Salgado-Gallegos, L. Elizondo-Montemayor and M. Hernández-Torre, *PLoS*
514 *One*, 2010, **5**, e10176.
- 515 22 S. Costa, A. Almeida, A. Castro and L. Domingues, *Front. Microbiol.*, 2014, 5, 63.
- 516 23 L. M. Rodríguez-Martínez, A. R. Marquez-Ipiña, F. López-Pacheco, R. Pérez-Chavarría, J.
517 C. González-Vázquez, E. González-González, G. Trujillo-de Santiago, C. A. Ponce-Ponce
518 de León, Y. S. Zhang, M. R. Dokmeci, A. Khademhosseini and M. M. Alvarez, *PLoS One*,
519 2015, **10**, e0135859.
- 520 24 P. B. Sánchez-Arreola, S. López-Uriarte, P. A. Marichal-Gallardo, J. C. González-Vázquez,
521 R. Pérez-Chavarría, P. Soto-Vázquez, F. López-Pacheco, A. Ramírez-Medrano, M. R.
522 Rocha-Pizaña and M. M. Álvarez, *Biotechnol. Prog.*, 2013, **29**, 896–908.
- 523 25 X. Chen, R. Li, Z. Pan, C. Qian, Y. Yang, R. You, J. Zhao, P. Liu, L. Gao, Z. Li, Q. Huang,
524 L. Xu, J. Tang, Q. Tian, W. Yao, L. Hu, X. Yan, X. Zhou, Y. Wu, K. Deng, Z. Zhang, Z.
525 Qian, Y. Chen and L. Ye, *Cell. Mol. Immunol.*, 2020, 17, 647–649.

